Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ARCUTIS BIOTHERAPEUTICS, INC. reported revenue of $376M, up 91.3% year over year. Operating margin was -3.3% and net margin -4.3%, on a free-cash-flow margin of -1.7% with capital expenditure at 0.2% of revenue. Every figure is computed directly from ARQT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $376M | -3.3% | -4.3% |
| FY2024 | $197M | -65.3% | -71.3% |
| FY2023 | $60M | -404.5% | -439.8% |
| FY2022 | $4M | -8183.0% | -8449.8% |
| FY2021 | $0M | n/a | n/a |
How does ARQT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.